Drug General Information
Drug ID
D09ZNV
Former ID
DNC014862
Drug Name
CGP-029482
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530101]
Structure
Download
2D MOL

3D MOL

Formula
C17H12N2O3
Canonical SMILES
C1=CC=C2C(=C1)C(=C3N2C4=CC=CC=C4C(=O)N3)CC(=O)O
InChI
1S/C17H12N2O3/c20-15(21)9-12-10-5-1-3-7-13(10)19-14-8-4-2-6-11(14)17(22)18-16(12)19/h1-8H,9H2,(H,18,22)(H,20,21)
InChIKey
INSBKYCYLCEBOD-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Casein kinase II, alpha chain Target Info Inhibitor [530101]
KEGG Pathway Ribosome biogenesis in eukaryotes
NF-kappa B signaling pathway
Wnt signaling pathway
Adherens junction
Tight junction
Measles
Herpes simplex infection
Epstein-Barr virus infection
NetPath Pathway FSH Signaling Pathway
Pathway Interaction Database BCR signaling pathway
Atypical NF-kappaB pathway
DNA-PK pathway in nonhomologous end joining
Presenilin action in Notch and Wnt signaling
Role of Calcineurin-dependent NFAT signaling in lymphocytes
E-cadherin signaling in the nascent adherens junction
Lissencephaly gene (LIS1) in neuronal migration and development
PDGFR-alpha signaling pathway
Signaling mediated by p38-alpha and p38-beta
Alpha-synuclein signaling
Reactome Condensation of Prometaphase Chromosomes
WikiPathways Mitotic Prometaphase
BDNF signaling pathway
TNF alpha Signaling Pathway
L1CAM interactions
References
Ref 530101Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. Epub 2009 Apr 22.Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.
Ref 530101Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. Epub 2009 Apr 22.Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.